Anke Schilhabel

667 total citations
14 papers, 352 citations indexed

About

Anke Schilhabel is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Anke Schilhabel has authored 14 papers receiving a total of 352 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Pathology and Forensic Medicine and 5 papers in Genetics. Recurrent topics in Anke Schilhabel's work include Lymphoma Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Microbial bioremediation and biosurfactants (4 papers). Anke Schilhabel is often cited by papers focused on Lymphoma Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Microbial bioremediation and biosurfactants (4 papers). Anke Schilhabel collaborates with scholars based in Germany, Netherlands and Austria. Anke Schilhabel's co-authors include Ruth A. Schmitz, Corinna Bang, Alexandra Perras, Maximilian Mora, Manuela-Raluca Pausan, Christine Moissl‐Eichinger, Kaisa Koskinen, Gabriele Diekert, Wilhelm Boland and Antonio J. Pierik and has published in prestigious journals such as Blood, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Anke Schilhabel

13 papers receiving 346 citations

Peers

Countries citing papers authored by Anke Schilhabel

Since Specialization

Citations

This map shows the geographic impact of Anke Schilhabel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anke Schilhabel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anke Schilhabel more than expected).

Fields of papers citing papers by Anke Schilhabel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anke Schilhabel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anke Schilhabel. The network helps show where Anke Schilhabel may publish in the future.

Co-authorship network of co-authors of Anke Schilhabel

This figure shows the co-authorship network connecting the top 25 collaborators of Anke Schilhabel. A scholar is included among the top collaborators of Anke Schilhabel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anke Schilhabel. Anke Schilhabel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	The gray area of RQ-PCR-based measurable residual disease: subdividing the “positive, below quantitative range” category 2024 ·Leukemia ·Michaela Kotrová, Eva Froňková, Michael Svatoň, Daniela Drandi, (unknown), (unknown), Jeremy Hancock, (unknown), Anke Schilhabel, Cornelia Eckert, Emmanuelle Clappier, Giovanni Cazzaniga, Beat W. Schäfer, Jacques J. M. van Dongen, Matthias Ritgen, Christiane Pott, Vincent H. J. van der Velden, Jan Trka, Monika Brüggemann	3
2	Patient specific real-time PCR in precision medicine – Validation of IG/TR based MRD assessment in lymphoid leukemia 2023 ·Frontiers in Oncology ·Anke Schilhabel, Monika Szczepanowski, Ellen J. van Gastel-Mol, (unknown), Jill Ray, Doris Kim, Michaela Nováková, (unknown), Vincent H. J. van der Velden, Sebastian Böettcher, Monika Brüggemann, Michael Kneba, Jacques J. M. van Dongen, Anton W. Langerak, Matthias Ritgen	1
3	Circulating Tumor DNA–Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax 2022 ·Clinical Cancer Research ·Moritz Fürstenau, Jonathan M. Weiss, (unknown), (unknown), Sandra Robrecht, Anna‐Maria Fink, Kirsten Fischer, Christof Schneider, Eugen Tausch, Stephan Stilgenbauer, Matthias Ritgen, Anke Schilhabel, Monika Brüggemann, Barbara Eichhorst, Michael Hallek, Paula Cramer	17
4	CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis 2022 ·Cancers ·Anke Schilhabel, (unknown), Paula Cramer, Julia von Tresckow, (unknown), Monika Szczepanowski, (unknown), Kirsten Fischer, Barbara Eichhorst, Sebastian Böttcher, Christof Schneider, Eugen Tausch, Monika Brüggemann, Michael Kneba, Michael Hallek, Matthias Ritgen	3
5	Disease Kinetics Measured By Circulating Tumor DNA Correlates with Treatment Response after Tafasitamab in Combination with R-CHOP with or without Lenalidomide in First Line Treatment of DLBCL 2021 ·Blood ·(unknown), Anke Schilhabel, Michaela Kotrová, Monika Brüggemann, Christian Kuffer, Derek Blair, Nikos Darzentas, Christiane Pott	0
6	A CONTINUOUS INDIVIDUALIZED RISK INDEX FOR REFINED OUTCOME PREDICTION AFTER TARGETED THERAPY FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CIRI‐CLL) 2021 ·Hematological Oncology ·Othman Al‐Sawaf, Mohammad Shahrokh Esfahani, (unknown), Eugen Tausch, Anke Schilhabel, Barbara Eichhorst, Stephan Stilgenbauer, Michael Hallek, Ash A. Alizadeh, David M. Kurtz, Kirsten Fischer	5
7	PREDICTION OF RELAPSE BY STANDARDIZED IG‐BASED ALLEL‐SPECIFIC QPCR, DDPCR AND AMPLICON NGS FOR MRD MONITORING IN MANTLE CELL LYMPHOMA: A COMPARATIVE ANALYSIS BY THE EU‐MCL NETWORK 2021 ·Hematological Oncology ·Christiane Pott, Elizabeth Macintyre, Marie-Hélène Delfau, (unknown), Anke Schilhabel, (unknown), (unknown), Nikos Darzentas, Michaela Kotrová, Frederick J. Schoen, Vincent Ribrag, Monika Brüggemann, Patrick Villarèse, Martin Dreyling, Olivier Hermine, Hanneke C. Kluin‐Nelemans, Linmiao Jiang, Eva Hoster	1
8	First Insights into the Diverse Human Archaeome: Specific Detection of Archaea in the Gastrointestinal Tract, Lung, and Nose and on Skin 2017 ·mBio ·Kaisa Koskinen, Manuela-Raluca Pausan, Alexandra Perras, (unknown), Corinna Bang, Maximilian Mora, Anke Schilhabel, Ruth A. Schmitz, Christine Moissl‐Eichinger	158
9	Effects of β-Lactam Antibiotics and Fluoroquinolones on Human Gut Microbiota in Relation to Clostridium difficile Associated Diarrhea 2014 ·PLoS ONE ·Henrik Knecht, Sven C. Neulinger, (unknown), Carolin Knecht, Anke Schilhabel, Ruth A. Schmitz, Alexandra Zimmermann, Vítor A. P. Martins dos Santos, Manuel Ferrer, Philip Rosenstiel, Stefan Schreiber, Anette Friedrichs, S. Ott	57
10	Effects of Antimicrobial Peptides on Methanogenic Archaea 2012 ·Antimicrobial Agents and Chemotherapy ·Corinna Bang, Anke Schilhabel, Katrin Weidenbach, (unknown), Torsten Goldmann, Thomas Gutsmann, Ruth A. Schmitz	30
11	The Ether-Cleaving Methyltransferase System of the Strict Anaerobe Acetobacterium dehalogenans : Analysis and Expression of the Encoding Genes ^▿ 2009 ·Journal of Bacteriology ·Anke Schilhabel, (unknown), Martin Vödisch, (unknown), Bernhard Schlott, Antonio J. Pierik, Gabriele Diekert	1
12	Reductive dehalogenation of brominated ethenes by Sulfurospirillum multivorans and Desulfitobacterium hafniense PCE‐S 2009 ·Environmental Microbiology ·Lidan Ye, Anke Schilhabel, Stefan Bartram, Wilhelm Boland, Gabriele Diekert	26
13	Enzymes involved in the anoxic utilization of phenyl methyl ethers by Desulfitobacterium hafniense DCB2 and Desulfitobacterium hafniense PCE-S 2008 ·Archives of Microbiology ·(unknown), Anke Schilhabel, Gabriele Diekert	14
14	The Ether-Cleaving Methyltransferase System of the Strict Anaerobe Acetobacterium dehalogenans : Analysis and Expression of the Encoding Genes 2008 ·Journal of Bacteriology ·Anke Schilhabel, (unknown), Martin Vödisch, (unknown), Bernhard Schlott, Antonio J. Pierik, Gabriele Diekert	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact